Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

December 7, 2022

Study Completion Date

December 8, 2022

Conditions
Vein OcclusionMacular Degeneration Choroidal NeovascularizationMacular EdemaDiabetic Retinopathy
Interventions
DRUG

Bromfenac Sodium 0.07%

Bromfenac sodium 0.07% is a nonsteroidal anti-inflammatory drug to be administered as one topical drop, one time 5 minutes prior to the regularly scheduled standard of care intravitreal injection.

DRUG

Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly

Loteprednol etabonate 0.38% ophthalmic gel is a steroidal drug to be administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.

DRUG

Propylene Glycol Preservative-free Artificial Tears

Propylene Glycol Preservative-free Artificial Tears is a placebo compartor administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.

Trial Locations (1)

63128

The Retina Institute, St Louis

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Retina Research Institute, LLC

OTHER

NCT07090044 - Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period | Biotech Hunter | Biotech Hunter